- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03533816
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Many patients with hematological malignancies require a bone marrow transplant for curative treatment. A matched sibling donor is optimal but may not be available. Therefore, a partially matched family member (haploidentical) may be a viable alternative. The incidence of graft vs. host disease, however, can become more of a significant, even fatal, factor with partial matches.
T-cells have been shown to be the key player in the post-transplant immune phenomena. The majority of T-cells are composed of alpha beta T-cells with a small minority of gamma delta T-cells, which are known to have the unique ability to kill malignant cells without antigen recognition.
This study proposes to extract, concentrate, and activate gamma delta T-cells from the peripheral blood to provide innate anti-tumor effect with minimal risk of GVHD. Safety and impact and/or the rate of GVHD will be evaluated.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- Recruiting
- University of Kansas Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The following criteria are used to enroll patients in the study before transplant.
Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:
- Acute myeloid leukemia [AML] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease
- Chronic myeloid leukemia [CML] in any chronic phase.
- Myelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease (with bone marrow blast count <10%).
- Acute lymphoblastic leukemia [ALL] in morphologic complete remission with high-risk features or relapsed disease.
- Negative test for donor-specific antibody within 28 days of starting conditioning regimen.
- Age Criteria: 19-65 years.
Organ Function Criteria: The following organ function testing should be done within 35 days before study registration.
- Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram.
- Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected.
- Renal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2.
- Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.
- Performance status: Karnofsky performance score (KPS) or Lansky score: ≥80.
- Hematopoietic cell transplant comorbidity index (HCT-CI) <3. Exception may be made on individual cases after discussion with the primary investigator.
- Consent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
The following criteria are required within 48 hours prior to infusion of the EAGD T cell product.
- Absence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture).
- NO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload.
NO clinically significant organ toxicity that are defined as follows:
- Heart failure with subnormal LVEF or clinical fluid overload.
- Elevated serum creatinine or subnormal creatinine clearance (either estimated or measured).
- Elevated total bilirubin ≥1.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) >5 x ULN.
- Hypoxemia requiring oxygen therapy
- NO acute graft versus host disease (any grade).
- Neutrophil engraftment.
Exclusion Criteria:
- Non-compliant patients.
- No appropriate caregivers identified.
- Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
- Active central nervous system (CNS) neoplastic involvement.
- Morbid obesity with body mass index >35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator).
- Patients with known allergy to DMSO.
- HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive.
- Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EAGD T-cell infusion (Phase I)
Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product.
This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
|
The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Other Names:
|
EXPERIMENTAL: EAGD T-cell infusion (Expansion)
Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product.
This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
|
The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I - Dose-limiting toxicity (DLT)
Time Frame: Baseline to Day 30
|
The dose escalation strategy will follow the Food and Drug Administration Guideline for design of early phase clinical trials of cellular therapy products.
|
Baseline to Day 30
|
Phase I - Severe acute adverse events following infusion of EAGD T-cells
Time Frame: Baseline to Day 100
|
Safety of the infusion will be based on the risk of treatment-related severe adverse events as identified in the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.
|
Baseline to Day 100
|
Expansion phase - Rate of acute GVHD
Time Frame: Baseline to Day 100
|
Monitoring for GVHD is assessed with Grade II-IV adverse events as identified by the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.
|
Baseline to Day 100
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expansion phase - Relapse following haploidentical HCT and PTCy with EAGD T-cell infusion
Time Frame: Baseline to 100 days
|
Number of subjects who have acute GVHD by day 100 post-HCT after infusion of EAGD T-cells
|
Baseline to 100 days
|
Expansion phase - Non-relapse mortality following haploidentical HCT and PTCy with EAGD T-cell infusion
Time Frame: Baseline to 100 days
|
Number of subjects who have no relapse by day 100 post-HCT after infusion
|
Baseline to 100 days
|
Expansion phase - Overall survival following haploidentical HCT and PTCy with EAGD T-cell infusion
Time Frame: Baseline to 100 days
|
Number of subjects who are living by day 100 post-HCT after infusion
|
Baseline to 100 days
|
Rate of one-year relapse-free survival (RFS)
Time Frame: Baseline to one year
|
Number of subjects living without relapse of disease after one year following HCT
|
Baseline to one year
|
Rate of one-year non-relapse mortality (NRM)
Time Frame: Baseline to one year
|
Number of subjects no longer living but not from disease relapse after one year following HCT
|
Baseline to one year
|
Rate of one-year overall survival (OS)
Time Frame: Baseline to one year
|
Number of subjects living after one year following HCT
|
Baseline to one year
|
Proportion of subjects with chronic GVHD at one year
Time Frame: Baseline to one year
|
Number of subjects with chronic GVHD after one year following HCT
|
Baseline to one year
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia, Lymphoid
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Other Study ID Numbers
- IIT-2018-Gamma-DeltaTcell
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on EAGD T-cell infusion (Phase I)
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruitingAcute T-lymphoblastic Leukemia | Acute T-lymphoblastic LymphomaChina
-
Massachusetts General HospitalDana-Farber Cancer Institute; University of RegensburgCompletedKidney Failure, Kidney TransplantUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnLymphoma | Lymphoma, B-Cell | LeukemiaUnited States
-
Mario ArpinatiEuropean CommissionRecruitingChronic Graft Versus Host DiseaseItaly
-
Wuhan Union Hospital, ChinaGuangzhou Bio-gene Technology Co., LtdNot yet recruitingSystemic Lupus Erythematosus
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Fundación Pública Andaluza para la gestión de la...RecruitingChronic Graft vs Host DiseaseSpain
-
H. Lee Moffitt Cancer Center and Research InstituteFlorida Department of HealthRecruitingAcute Myeloid LeukemiaUnited States